177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model

Molecular Pharmaceutics

Volumn 11, Issue 3, 2014, Pages 800-807

  Liu, Zhaofei ^a   Ma, Teng ^a   Liu, Hao ^a   Jin, Zhongxia ^a   Sun, Xianlei ^a   Zhao, Huiyun ^a   Shi, Jiyun ^a   Jia, Bing ^a   Li, Fang ^b   Wang, Fan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

antibody; epidermal growth factor receptor; small animal imaging; targeted therapy

Indexed keywords

CETUXIMAB; CETUXIMAB LU 177; EPIDERMAL GROWTH FACTOR RECEPTOR; LUTETIUM 177; PANITUMUMAB; PANITUMUMAB LU 177; TETRAXETAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; LUTETIUM; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; FEMALE; HEAD AND NECK CARCINOMA; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; DRUG SCREENING; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; METABOLISM; RADIATION RESPONSE; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; FEMALE; HEAD AND NECK NEOPLASMS; LUTETIUM; MICE; MICE, INBRED BALB C; RADIOIMMUNOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901743383     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4005047     Document Type: Article

References (30)

1. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J. Clin. Oncol. 2003, 21 (14) 2787-99
2. Huang, S. M.; Harari, P. M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results Invest. New Drugs 1999, 17 (3) 259-69
3. Salomon, D. S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies Crit. Rev. Oncol. Hematol. 1995, 19 (3) 183-232
4. Wheeler, D. L.; Dunn, E. F.; Harari, P. M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat. Rev. Clin. Oncol. 2010, 7 (9) 493-507
5. Giusti, R. M.; Shastri, K. A.; Cohen, M. H.; Keegan, P.; Pazdur, R. FDA drug approval summary: panitumumab (Vectibix) Oncologist 2007, 12 (5) 577-83
6. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N. Engl. J. Med. 2004, 351 (4) 337-45
7. Cai, W.; Chen, K.; He, L.; Cao, Q.; Koong, A.; Chen, X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody Eur. J. Nucl. Med. Mol. Imaging 2007, 34 (6) 850-8
8. Hoeben, B. A.; Molkenboer-Kuenen, J. D.; Oyen, W. J.; Peeters, W. J.; Kaanders, J. H.; Bussink, J.; Boerman, O. C. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model Int. J. Cancer 2011, 129 (4) 870-8
9. Nayak, T. K.; Garmestani, K.; Baidoo, K. E.; Milenic, D. E.; Brechbiel, M. W. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma J. Nucl. Med. 2010, 51 (6) 942-50
10. Liu, Z.; Liu, Y.; Jia, B.; Zhao, H.; Jin, X.; Li, F.; Chen, X.; Wang, F. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab Mol. Cancer Ther. 2010, 9 (8) 2297-308
11. Rosenthal, E. L.; Kulbersh, B. D.; King, T.; Chaudhuri, T. R.; Zinn, K. R. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts Mol. Cancer Ther. 2007, 6 (4) 1230-8
12. Van Cutsem, E.; Kohne, C. H.; Hitre, E.; Zaluski, J.; Chang Chien, C. R.; Makhson, A.; D'Haens, G.; Pinter, T.; Lim, R.; Bodoky, G.; Roh, J. K.; Folprecht, G.; Ruff, P.; Stroh, C.; Tejpar, S.; Schlichting, M.; Nippgen, J.; Rougier, P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N. Engl. J. Med. 2009, 360 (14) 1408-17
13. Van Cutsem, E.; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J. L.; Van Laethem, J. L.; Maurel, J.; Richardson, G.; Wolf, M.; Amado, R. G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer J. Clin. Oncol. 2007, 25 (13) 1658-64
14. Liu, L.; Cao, Y.; Tan, A.; Liao, C.; Gao, F. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials Cancer Chemother. Pharmacol. 2010, 65 (5) 849-61
15. Chung, K. Y.; Shia, J.; Kemeny, N. E.; Shah, M.; Schwartz, G. K.; Tse, A.; Hamilton, A.; Pan, D.; Schrag, D.; Schwartz, L.; Klimstra, D. S.; Fridman, D.; Kelsen, D. P.; Saltz, L. B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J. Clin. Oncol. 2005, 23 (9) 1803-10
16. Wild, R.; Fager, K.; Flefleh, C.; Kan, D.; Inigo, I.; Castaneda, S.; Luo, F. R.; Camuso, A.; McGlinchey, K.; Rose, W. C. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels Mol. Cancer Ther. 2006, 5 (1) 104-13
17. Niu, G.; Sun, X.; Cao, Q.; Courter, D.; Koong, A.; Le, Q. T.; Gambhir, S. S.; Chen, X. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma Clin. Cancer Res. 2010, 16 (7) 2095-105
18. Fischer, E.; Grunberg, J.; Cohrs, S.; Hohn, A.; Waldner-Knogler, K.; Jeger, S.; Zimmermann, K.; Novak-Hofer, I.; Schibli, R. L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer Int. J. Cancer 2012, 130 (11) 2715-21
19. Sharkey, R. M.; Goldenberg, D. M. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates Ca-Cancer J. Clin. 2006, 56 (4) 226-43
20. Huang, J.; Cui, L.; Wang, F.; Liu, Z. PET tracers based on (86)Y Curr. Radiopharm. 2011, 4 (2) 122-30
21. Nayak, T. K.; Brechbiel, M. W. 86Y based PET radiopharmaceuticals: radiochemistry and biological applications Med. Chem. 2011, 7 (5) 380-8
22. Liu, Z.; Yu, Z.; He, W.; Ma, S.; Sun, L.; Wang, F. In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model Cancer Biother. Radiopharm. 2009, 24 (1) 15-24
23. Liu, Z.; Jia, B.; Zhao, H.; Chen, X.; Wang, F. Specific targeting of human integrin alpha(v)beta (3) with (111)In-labeled Abegrin in nude mouse models Mol. Imaging Biol. 2011, 13 (1) 112-20
24. Saltz, L. B.; Meropol, N. J.; Loehrer, P. J., Sr; Needle, M. N.; Kopit, J.; Mayer, R. J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J. Clin. Oncol. 2004, 22 (7) 1201-8
25. Hebbar, M.; Wacrenier, A.; Desauw, C.; Romano, O.; Cattan, S.; Triboulet, J. P.; Pruvot, F. R. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer Anticancer Drugs 2006, 17 (7) 855-7
26. Nayak, T. K.; Garmestani, K.; Milenic, D. E.; Baidoo, K. E.; Brechbiel, M. W. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts PLoS One 2011, 6 (3) e18198
27. Astsaturov, I.; Cohen, R. B.; Harari, P. M. EGFR-targeting monoclonal antibodies in head and neck cancer Curr. Cancer Drug Targets 2006, 6 (8) 691-710
28. Fujimori, K.; Covell, D. G.; Fletcher, J. E.; Weinstein, J. N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier J. Nucl. Med. 1990, 31 (7) 1191-8
29. van Osdol, W.; Fujimori, K.; Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier" Cancer Res. 1991, 51 (18) 4776-84
30. Rudnick, S. I.; Adams, G. P. Affinity and avidity in antibody-based tumor targeting Cancer Biother. Radiopharm. 2009, 24 (2) 155-61